Phase 2 trial of ibudilast in progressive multiple sclerosis Academic Article uri icon

Overview

MeSH Major

  • Brain
  • Multiple Sclerosis, Chronic Progressive
  • Phosphodiesterase Inhibitors
  • Pyridines

abstract

  • In a phase 2 trial involving patients with progressive multiple sclerosis, ibudilast was associated with slower progression of brain atrophy than placebo but was associated with higher rates of gastrointestinal side effects, headache, and depression. (Funded by the National Institute of Neurological Disorders and Stroke and others; NN102/SPRINT-MS ClinicalTrials.gov number, NCT01982942 .).

authors

publication date

  • August 30, 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1803583

PubMed ID

  • 30157388

Additional Document Info

start page

  • 846

end page

  • 855

volume

  • 379

number

  • 9